- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07399977
Bruke en blodprøve og et programvareverktøy for å veilede behandling av venøs tromboembolisme
En ikke-randomisert studie som bruker DNA flytende biopsier for å veilede antikoagulasjon for pasienter med kreft-assosiert tromboembolisme
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Jeffrey Zwicker, MD
- Telefonnummer: 646-608-3723
- E-post: zwickerj@mskcc.org
Studer Kontakt Backup
- Navn: Justin Jee, MD, PhD
- Telefonnummer: 646-608-4409
- E-post: jeej@mskcc.org
Studiesteder
-
-
-
Sydney, Australia, 2065
- Har ikke rekruttert ennå
- Royal North Shore Hospital, Australia
-
Ta kontakt med:
- Adrian Lee, MBBS, FRACP PhD
- Telefonnummer: 02 8037 4100
-
-
-
-
New Jersey
-
Basking Ridge, New Jersey, Forente stater, 07920
- Rekruttering
- Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities)
-
Ta kontakt med:
- Justin Jee, MD, PhD
- Telefonnummer: 646-608-4409
-
Middletown, New Jersey, Forente stater, 07748
- Rekruttering
- Memorial Sloan Kettering Monmouth (All Protocol Activities)
-
Ta kontakt med:
- Justin Jee, MD, PhD
- Telefonnummer: 646-608-4409
-
Montvale, New Jersey, Forente stater, 07645
- Rekruttering
- Memorial Sloan Kettering Bergen (All Protocol Activities)
-
Ta kontakt med:
- Justin Jee, MD, PhD
- Telefonnummer: 646-608-4409
-
-
New York
-
Commack, New York, Forente stater, 11725
- Rekruttering
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
-
Ta kontakt med:
- Justin Jee, MD, PhD
- Telefonnummer: 646-608-4409
-
Harrison, New York, Forente stater, 10604
- Rekruttering
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
Ta kontakt med:
- Justin Jee, MD, PhD
- Telefonnummer: 646-608-4409
-
New York, New York, Forente stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)
-
Ta kontakt med:
- Justin Jee, MD, PhD
- Telefonnummer: 646-608-4409
-
Rockville Centre, New York, Forente stater, 11553
- Rekruttering
- Memorial Sloan Kettering Nassau (All protocol activities)
-
Ta kontakt med:
- Justin Jee, MD, PhD
- Telefonnummer: 646-608-4409
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 with a history of cancer-associated VTE (objectively confirmed symptomatic or incidental/unsuspected proximal lower-limb DVT, symptomatic pulmonary embolism [PE] or incidental PE in a segmental or more proximal pulmonary artery) and completion of between 3 and 12 months of anticoagulation with enoxaparin, dalteparin,rivaroxaban, or apixaban without current VTE-related symptoms (imaging to confirm resolution not required).
Diagnosis of DVT requires evidence of one or more filling defects at compression ultrasonography, venography, CT venography, or MR venography involving at least the popliteal or more proximal veins.
Diagnosis of PE requires an intraluminal filling defect in segmental or more proximal arteries.
-
Diagnosis of one of the following solid tumors in either advanced (i.e. unresectable) stage or receiving systemic anticancer treatment within six weeks of enrollment (maintenance therapy included):
- breast cancer regardless of cytotoxic-chemotherapy status
- hepatobiliary cancer regardless of cytotoxic-chemotherapy status
- prostate cancer regardless of cytotoxic-chemotherapy status
- non-small cell lung cancer with cytotoxic-chemotherapy received within 30 days
- pancreatic cancer with cytotoxic-chemotherapy received within 30 days
- bladder cancer with cytotoxic-chemotherapy received within 30 days
-
Signed and dated informed consent by study participant/Legally Authorized Representative (LAR).
Exclusion Criteria:
- Contraindication to ongoing anticoagulation
- Contraindication to discontinuation of anticoagulation (examples include but not limited to: known antiphospholipid syndrome or factor V leiden, active arterial thrombus, catheter-associated thrombus, on anticoagulation for atrial fibrillation or other non-oncologic reasons)
- History of major bleeding in the last six months (major bleeding defined as fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; bleeding that necessitates acute surgical intervention; bleeding causing a fall in hemoglobin levels of 1.24 mmol/L (2 g/dL or greater) or more; or bleeding leading to a transfusion of 2 U or more of whole blood or red cells).
- Known diagnosis of disseminated intravascular coagulation (DIC)
- Suspicion for tumor thrombus on the imaging leading to original diagnosis of VTE
- Enrolled in hospice care
- Currently has inferior vena cava (IVC) filter
- Diagnosis of an active hematologic malignancy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: High risk for recurrent Venous Thromboembolism/VTE
Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk. |
MSK-ACCESS is a ctDNA sequencing assay Machine learning Venous Thromboembolism/VTE risk score mode |
|
Eksperimentell: Low-risk for recurrent Venous Thromboembolism/VTE
Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk. |
MSK-ACCESS is a ctDNA sequencing assay Machine learning Venous Thromboembolism/VTE risk score mode |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cumulative incidence of recurrent Venous Thromboembolism/VTE
Tidsramme: 6 months
|
Evaluate the cumulative incidence of recurrent Venous Thromboembolism/VTE at 6 months following discontinuation of anticoagulation in participants with low risk DNA liquid biopsy-based model. |
6 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Justine Jee, MD, PhD, Memorial Sloan Kettering Cancer Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 25-095
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .